Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
Immunic, Inc. reports that Alyeska-affiliated reporting persons beneficially own 6,332,000 shares of Common Stock, representing 4.85% of the class. The stake, reported as of March 31, 2026, includes 4,041,000 shares issuable upon exercise of warrants and 2,291,000 shares issuable upon exercise of pre-funded warrants. The filing shows shared voting and dispositive power over the 6,332,000 shares. The number of shares outstanding is listed as 130,464,825 per the Form S-3 dated April 2, 2026.
IMMUNIC, INC. files an Amendment No. 2 to a Schedule 13G/A noting an "exit filing" by certain reporting persons. The amendment states that, as of May 15, 2026, 683 Capital Partners, LP, 683 Capital Management, LLC and Ari Zweiman may be deemed to beneficially own 474,200 shares (including 229,200 exercisable warrants), representing 3.4% of the company's common stock. The filing cites 13,621,526 shares outstanding as of April 28, 2026 as the base for the percentage calculation and includes the verbatim comment that the Reporting Persons "no longer beneficially own more than five percent" of the issuer.
Immunic, Inc. reported first quarter 2026 results and highlighted a large private financing to fund its multiple sclerosis programs. For the three months ended March 31, 2026, the company recorded a net loss of $32,588 thousand, driven by research and development expenses of $25,626 thousand and general and administrative expenses of $7,609 thousand.
In February, Immunic closed an oversubscribed private placement of up to $400 million in gross proceeds, with $200 million received upfront, which management expects to fund operations through completion of the phase 3 ENSURE trials in relapsing multiple sclerosis and a planned RMS New Drug Application submission in mid-2027. Cash and cash equivalents increased to $186,629 thousand as of March 31, 2026, and total stockholders’ equity improved to $151,233 thousand, reflecting the new capital despite ongoing operating losses.
Immunic, Inc. reported a first-quarter 2026 net loss of $32.6 million, wider than the $25.5 million loss a year earlier, as operating expenses rose to $33.2 million driven mainly by research and development spending of $25.6 million.
Financing activity significantly strengthened the balance sheet. A February 2026 private placement of pre-funded and common warrants generated gross proceeds of $200 million and net proceeds of $187.3 million, lifting cash and cash equivalents to $186.6 million as of March 31, 2026, compared with $15.5 million at year-end 2025. Management states these funds are expected to support operations for more than twelve months.
The company also completed a 1-for-10 reverse stock split effective April 27, 2026, regained compliance with Nasdaq’s minimum bid price requirement, and continued advancing its late-stage pipeline, including Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis and a Phase 2 program in progressive multiple sclerosis.
Immunic, Inc. Schedule 13G: A group led by Millennium-affiliated entities filed a joint Schedule 13G reporting shared beneficial positions in Immunic common stock. Integrated Core Strategies (US) LLC reported 743,281 shares (5.4%). Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each reported 793,621 shares (5.7%). The filing references a Joint Filing Agreement dated May 5, 2026 and notes shares are held by entities subject to voting and investment discretion by Millennium-affiliated managers.
Immunic, Inc. amends its shelf registration to reflect a 1-for-10 reverse stock split and to register for resale up to 45,815,180 shares of common stock by selling stockholders. The shares consist of up to 22,907,590 pre-funded warrant shares and 22,907,590 common warrant shares originally issued in a February 12, 2026 private placement.
The filing states the company will not receive proceeds from resale transactions, although it would receive proceeds if the warrants are exercised for cash; aggregate exercise proceeds are approximately $200.0M. The prospectus notes the Resale Shares equal ~336% of outstanding common stock (post-split basis) and discloses a Nasdaq closing price of $9.98 per share on April 27, 2026.
Immunic, Inc. granted Chief Medical Officer Michael A. Panzara a stock option covering 300,000 shares of common stock. The option has an exercise price of $8.80 per share and expires on April 24, 2036, representing a compensation-related award rather than an open-market trade.
According to the vesting terms, 50% of the underlying 300,000 shares will vest on April 24, 2027, and the remaining 50% will vest in 24 equal monthly installments, as long as he remains an employee of Immunic in good standing through each vesting date.
IMMUNIC, INC. filed an initial Form 3 for Chief Medical Officer Michael A. Panzara, establishing his status as a reporting person for the company’s securities. The filing does not list any buy, sell, or derivative transactions and serves as a baseline disclosure of insider reporting obligations.
Immunic, Inc. appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer effective April 24, 2026, succeeding co-founder Andreas Muehler, M.D., M.B.A., who resigned as CMO and will transition to a consulting role.
Dr. Panzara brings more than 25 years of neurology drug development experience from Neurvati, Wave Life Sciences, Sanofi Genzyme and Biogen, including work on several approved multiple sclerosis therapies. His employment terms include a $600,000 annual base salary, a target bonus of at least 50% of base salary, a $125,000 signing bonus and stock options to purchase 300,000 shares that vest over three years. Dr. Muehler will receive 12 months of base-salary severance from both Immunic and Immunic AG, full vesting of outstanding equity awards and a 10‑month consulting arrangement at $10,000 per month.